Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 5th edition, 486 pages Free download

Prostate Cancer

Free Subscription Articles published in Eur Radiol Retrieve available abstracts of 81 articles: HTML format

Single Articles

November 2020
1. PADHANI AR, Schoots IG, Turkbey B, Giannarini G, et al
   A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis.
   Eur Radiol. 2020 Nov 25. pii: 10.1007/s00330-020-07527.
   PubMed     Abstract available
   
   
   
2. CAGLIC I, Sushentsev N, Gnanapragasam VJ, Sala E, et al
   MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance.
   Eur Radiol. 2020 Nov 16. pii: 10.1007/s00330-020-07336.
   PubMed     Abstract available
   
   
   
3. OTTOSSON F, Baco E, Lauritzen PM, Rud E, et al
   The prevalence and locations of bone metastases using whole-body MRI in treatment-naive intermediate- and high-risk prostate cancer.
   Eur Radiol. 2020 Nov 3. pii: 10.1007/s00330-020-07363.
   PubMed     Abstract available
   
   
   September 2020
4. GIGANTI F, Stabile A, Stavrinides V, Osinibi E, et al
   Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort.
   Eur Radiol. 2020 Sep 30. pii: 10.1007/s00330-020-07256.
   PubMed     Abstract available
   
   
   
5. SHIRADKAR R, Panda A, Leo P, Janowczyk A, et al
   Correction to: T1 and T2 MR fingerprinting measurements of prostate cancer and prostatitis correlate with deep learning-derived estimates of epithelium, lumen, and stromal composition on corresponding whole mount histopathology.
   Eur Radiol. 2020 Sep 18. pii: 10.1007/s00330-020-07285.
   PubMed     Abstract available
   
   
   
6. HU L, Zhou DW, Fu CX, Benkert T, et al
   Advanced zoomed diffusion-weighted imaging vs. full-field-of-view diffusion-weighted imaging in prostate cancer detection: a radiomic features study.
   Eur Radiol. 2020 Sep 16. pii: 10.1007/s00330-020-07227.
   PubMed     Abstract available
   
   
   
7. KIM CH, Kim CK, Park JJ, Park SY, et al
   Yield of concurrent systemic biopsy during MRI-targeted biopsy according to Prostate Imaging Reporting and Data System version 2 in patients with suspected prostate cancer.
   Eur Radiol. 2020 Sep 10. pii: 10.1007/s00330-020-07167.
   PubMed     Abstract available
   
   
   
8. SHIRADKAR R, Panda A, Leo P, Janowczyk A, et al
   T1 and T2 MR fingerprinting measurements of prostate cancer and prostatitis correlate with deep learning-derived estimates of epithelium, lumen, and stromal composition on corresponding whole mount histopathology.
   Eur Radiol. 2020 Sep 2. pii: 10.1007/s00330-020-07214.
   PubMed     Abstract available
   
   
   August 2020
9. GUGLIANDOLO SG, Pepa M, Isaksson LJ, Marvaso G, et al
   MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218).
   Eur Radiol. 2020 Aug 27. pii: 10.1007/s00330-020-07105.
   PubMed     Abstract available
   
   
   
10. SUN C, Wang S, Chatterjee A, Medved M, et al
    T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy.
    Eur Radiol. 2020 Aug 12. pii: 10.1007/s00330-020-07127.
    PubMed     Abstract available
    
    
    July 2020
11. HIREMATH A, Shiradkar R, Merisaari H, Prasanna P, et al
    Test-retest repeatability of a deep learning architecture in detecting and segmenting clinically significant prostate cancer on apparent diffusion coefficient (ADC) maps.
    Eur Radiol. 2020 Jul 23. pii: 10.1007/s00330-020-07065.
    PubMed     Abstract available
    
    
    
12. BERNATZ S, Ackermann J, Mandel P, Kaltenbach B, et al
    Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features.
    Eur Radiol. 2020 Jul 16. pii: 10.1007/s00330-020-07064.
    PubMed     Abstract available
    
    
    June 2020
13. CUOCOLO R, Cipullo MB, Stanzione A, Romeo V, et al
    Machine learning for the identification of clinically significant prostate cancer on MRI: a meta-analysis.
    Eur Radiol. 2020 Jun 30. pii: 10.1007/s00330-020-07027.
    PubMed     Abstract available
    
    
    
14. ARIF M, Schoots IG, Castillo Tovar J, Bangma CH, et al
    Clinically significant prostate cancer detection and segmentation in low-risk patients using a convolutional neural network on multi-parametric MRI.
    Eur Radiol. 2020 Jun 27. pii: 10.1007/s00330-020-07008.
    PubMed     Abstract available
    
    
    
15. DENIFFEL D, Abraham N, Namdar K, Dong X, et al
    Using decision curve analysis to benchmark performance of a magnetic resonance imaging-based deep learning model for prostate cancer risk assessment.
    Eur Radiol. 2020 Jun 26. pii: 10.1007/s00330-020-07030.
    PubMed     Abstract available
    
    
    
16. ULLRICH T, Arsov C, Quentin M, Mones F, et al
    Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.
    Eur Radiol. 2020 Jun 26. pii: 10.1007/s00330-020-06997.
    PubMed     Abstract available
    
    
    
17. SVIRYDENKA H, Muehlematter UJ, Nagel HW, Delso G, et al
    (68)Ga-PSMA-11 dose reduction for dedicated pelvic imaging with simultaneous PET/MR using TOF BSREM reconstructions.
    Eur Radiol. 2020;30:3188-3197.
    PubMed     Abstract available
    
    
    May 2020
18. DE ROOIJ M, Israel B, Tummers M, Ahmed HU, et al
    ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training.
    Eur Radiol. 2020 May 19. pii: 10.1007/s00330-020-06929.
    PubMed     Abstract available
    
    
    April 2020
19. WINKEL DJ, Breit HC, Block TK, Boll DT, et al
    High spatiotemporal resolution dynamic contrast-enhanced MRI improves the image-based discrimination of histopathology risk groups of peripheral zone prostate cancer: a supervised machine learning approach.
    Eur Radiol. 2020 Apr 23. pii: 10.1007/s00330-020-06849.
    PubMed     Abstract available
    
    
    
20. LIECHTI MR, Muehlematter UJ, Schneider AF, Eberli D, et al
    Manual prostate cancer segmentation in MRI: interreader agreement and volumetric correlation with transperineal template core needle biopsy.
    Eur Radiol. 2020 Apr 19. pii: 10.1007/s00330-020-06786.
    PubMed     Abstract available
    
    
    
21. ALVES JR, Muglia VF, Lucchesi FR, Faria RAOG, et al
    Independent external validation of nomogram to predict extracapsular extension in patients with prostate cancer.
    Eur Radiol. 2020 Apr 19. pii: 10.1007/s00330-020-06839.
    PubMed     Abstract available
    
    
    
22. GIGANTI F, Pecoraro M, Stavrinides V, Stabile A, et al
    Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study.
    Eur Radiol. 2020;30:2082-2090.
    PubMed     Abstract available
    
    
    March 2020
23. RUDOLPH MM, Baur ADJ, Haas M, Cash H, et al
    Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer.
    Eur Radiol. 2020 Mar 26. pii: 10.1007/s00330-020-06773.
    PubMed     Abstract available
    
    
    February 2020
24. LECOUVET FE, Pasoglou V, Van Nieuwenhove S, Van Haver T, et al
    Shortening the acquisition time of whole-body MRI: 3D T1 gradient echo Dixon vs fast spin echo for metastatic screening in prostate cancer.
    Eur Radiol. 2020 Feb 17. pii: 10.1007/s00330-019-06515.
    PubMed     Abstract available
    
    
    
25. ZHANG Y, Wells SA, Triche BL, Kelcz F, et al
    Stimulated-echo diffusion-weighted imaging with moderate b values for the detection of prostate cancer.
    Eur Radiol. 2020 Feb 16. pii: 10.1007/s00330-020-06689.
    PubMed     Abstract available
    
    
    December 2019
26. FISCHBACH F, Hass P, Schindele D, Genseke P, et al
    MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL).
    Eur Radiol. 2019 Dec 11. pii: 10.1007/s00330-019-06505.
    PubMed     Abstract available
    
    
    
27. QUENTIN M, Arsov C, Ullrich T, Valentin B, et al
    Comparison of analgesic techniques in MRI-guided in-bore prostate biopsy.
    Eur Radiol. 2019;29:6965-6970.
    PubMed     Abstract available
    
    
    November 2019
28. BLEKER J, Kwee TC, Dierckx RAJO, de Jong IJ, et al
    Multiparametric MRI and auto-fixed volume of interest-based radiomics signature for clinically significant peripheral zone prostate cancer.
    Eur Radiol. 2019 Nov 27. pii: 10.1007/s00330-019-06488.
    PubMed     Abstract available
    
    
    October 2019
29. WILDEBOER RR, Mannaerts CK, van Sloun RJG, Budaus L, et al
    Automated multiparametric localization of prostate cancer based on B-mode, shear-wave elastography, and contrast-enhanced ultrasound radiomics.
    Eur Radiol. 2019 Oct 10. pii: 10.1007/s00330-019-06436.
    PubMed     Abstract available
    
    
    September 2019
30. ANTONELLI M, Johnston EW, Dikaios N, Cheung KK, et al
    Correction to: Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists.
    Eur Radiol. 2019 Sep 10. pii: 10.1007/s00330-019-06429.
    PubMed     Abstract available
    
    
    August 2019
31. ALDOJ N, Lukas S, Dewey M, Penzkofer T, et al
    Semi-automatic classification of prostate cancer on multi-parametric MR imaging using a multi-channel 3D convolutional neural network.
    Eur Radiol. 2019 Aug 29. pii: 10.1007/s00330-019-06417.
    PubMed     Abstract available
    
    
    
32. AHN H, Hwang SI, Lee HJ, Suh HS, et al
    Prediction of extraprostatic extension on multi-parametric magnetic resonance imaging in patients with anterior prostate cancer.
    Eur Radiol. 2019 Aug 5. pii: 10.1007/s00330-019-06340.
    PubMed     Abstract available
    
    
    July 2019
33. DOMACHEVSKY L, Bernstine H, Goldberg N, Nidam M, et al
    Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
    Eur Radiol. 2019 Jul 22. pii: 10.1007/s00330-019-06353.
    PubMed     Abstract available
    
    
    June 2019
34. ANTONELLI M, Johnston EW, Dikaios N, Cheung KK, et al
    Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists.
    Eur Radiol. 2019 Jun 11. pii: 10.1007/s00330-019-06244.
    PubMed     Abstract available
    
    
    
35. RICHENBERG J, Logager V, Panebianco V, Rouviere O, et al
    The primacy of multiparametric MRI in men with suspected prostate cancer.
    Eur Radiol. 2019 Jun 6. pii: 10.1007/s00330-019-06166.
    PubMed     Abstract available
    
    
    May 2019
36. XIANG LH, Fang Y, Wan J, Xu G, et al
    Shear-wave elastography: role in clinically significant prostate cancer with false-negative magnetic resonance imaging.
    Eur Radiol. 2019 May 29. pii: 10.1007/s00330-019-06274.
    PubMed     Abstract available
    
    
    April 2019
37. BONEKAMP D, Schelb P, Wiesenfarth M, Kuder TA, et al
    Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate.
    Eur Radiol. 2019;29:1820-1830.
    PubMed     Abstract available
    
    
    March 2019
38. ALESSI S, Pricolo P, Summers P, Femia M, et al
    Low PI-RADS assessment category excludes extraprostatic extension (>/=pT3a) of prostate cancer: a histology-validated study including 301 operated patients.
    Eur Radiol. 2019 Mar 18. pii: 10.1007/s00330-019-06092.
    PubMed     Abstract available
    
    
    
39. JENDOUBI S, Wagner M, Montagne S, Ezziane M, et al
    MRI for prostate cancer: can computed high b-value DWI replace native acquisitions?
    Eur Radiol. 2019 Mar 18. pii: 10.1007/s00330-019-06085.
    PubMed     Abstract available
    
    
    
40. CAGLIC I, Povalej Brzan P, Warren AY, Bratt O, et al
    Defining the incremental value of 3D T2-weighted imaging in the assessment of prostate cancer extracapsular extension.
    Eur Radiol. 2019 Mar 18. pii: 10.1007/s00330-019-06070.
    PubMed     Abstract available
    
    
    
41. PURYSKO AS, Magi-Galluzzi C, Mian OY, Sittenfeld S, et al
    Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings.
    Eur Radiol. 2019 Mar 7. pii: 10.1007/s00330-019-06114.
    PubMed     Abstract available
    
    
    January 2019
42. BONEKAMP D, Wolf MB, Roethke MC, Pahernik S, et al
    Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate.
    Eur Radiol. 2019;29:299-308.
    PubMed     Abstract available
    
    
    December 2018
43. JOHNSTON EW, Latifoltojar A, Sidhu HS, Ramachandran N, et al
    Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
    Eur Radiol. 2018 Dec 5. pii: 10.1007/s00330-018-5813.
    PubMed     Abstract available
    
    
    
44. DOMACHEVSKY L, Goldberg N, Bernstine H, Nidam M, et al
    Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.
    Eur Radiol. 2018;28:5275-5283.
    PubMed     Abstract available
    
    
    November 2018
45. DIKAIOS N, Giganti F, Sidhu HS, Johnston EW, et al
    Multi-parametric MRI zone-specific diagnostic model performance compared with experienced radiologists for detection of prostate cancer.
    Eur Radiol. 2018 Nov 19. pii: 10.1007/s00330-018-5799.
    PubMed     Abstract available
    
    
    
46. DINIS FERNANDES C, Ghobadi G, van der Poel HG, de Jong J, et al
    Quantitative 3-T multi-parametric MRI and step-section pathology of recurrent prostate cancer patients after radiation therapy.
    Eur Radiol. 2018 Nov 12. pii: 10.1007/s00330-018-5819.
    PubMed     Abstract available
    
    
    
47. LARBI A, Omoumi P, Pasoglou V, Michoux N, et al
    Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences.
    Eur Radiol. 2018 Nov 9. pii: 10.1007/s00330-018-5796.
    PubMed     Abstract available
    
    
    
48. OVERDUIN CG, Heidkamp J, Rothgang E, Barentsz JO, et al
    Fast 3-T MR-guided transrectal prostate biopsy using an in-room tablet device for needle guide alignment: a feasibility study.
    Eur Radiol. 2018;28:4824-4831.
    PubMed     Abstract available
    
    
    October 2018
49. GREER MD, Lay N, Shih JH, Barrett T, et al
    Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study.
    Eur Radiol. 2018;28:4407-4417.
    PubMed     Abstract available
    
    
    August 2018
50. DYRBERG E, Hendel HW, Huynh THV, Klausen TW, et al
    (68)Ga-PSMA-PET/CT in comparison with (18)F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.
    Eur Radiol. 2018 Aug 21. pii: 10.1007/s00330-018-5682.
    PubMed     Abstract available
    
    
    
51. KRISHNA S, Schieda N, McInnes MD, Flood TA, et al
    Diagnosis of transition zone prostate cancer using T2-weighted (T2W) MRI: comparison of subjective features and quantitative shape analysis.
    Eur Radiol. 2018 Aug 13. pii: 10.1007/s00330-018-5664.
    PubMed     Abstract available
    
    
    June 2018
52. FISCHBACH F, Wien L, Krueger S, Schnackenburg B, et al
    Feasibility study of MR-guided transgluteal targeted in-bore biopsy for suspicious lesions of the prostate at 3 Tesla using a freehand approach.
    Eur Radiol. 2018;28:2690-2699.
    PubMed     Abstract available
    
    
    May 2018
53. PIERRE T, Cornud F, Colleter L, Beuvon F, et al
    Diffusion-weighted imaging of the prostate: should we use quantitative metrics to better characterize focal lesions originating in the peripheral zone?
    Eur Radiol. 2018;28:2236-2245.
    PubMed     Abstract available
    
    
    April 2018
54. GHAI S, Perlis N, Lindner U, Hlasny E, et al
    Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.
    Eur Radiol. 2018 Apr 25. pii: 10.1007/s00330-018-5409.
    PubMed     Abstract available
    
    
    
55. LOTTE R, Lafourcade A, Mozer P, Conort P, et al
    Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?
    Eur Radiol. 2018 Apr 9. pii: 10.1007/s00330-018-5352.
    PubMed     Abstract available
    
    
    
56. WINFIELD JM, Poillucci G, Blackledge MD, Collins DJ, et al
    Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI.
    Eur Radiol. 2018;28:1687-1691.
    PubMed     Abstract available
    
    
    
57. POLANEC SH, Lazar M, Wengert GJ, Bickel H, et al
    3D T2-weighted imaging to shorten multiparametric prostate MRI protocols.
    Eur Radiol. 2018;28:1634-1641.
    PubMed     Abstract available
    
    
    March 2018
58. SHIN T, Kaji Y, Shukuya T, Nozaki M, et al
    Significant changes of T2 value in the peripheral zone and seminal vesicles after ejaculation.
    Eur Radiol. 2018;28:1009-1015.
    PubMed     Abstract available
    
    
    January 2018
59. SELNAES KM, Kruger-Stokke B, Elschot M, Willoch F, et al
    (18)F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.
    Eur Radiol. 2018 Jan 2. pii: 10.1007/s00330-017-5213.
    PubMed     Abstract available
    
    
    
60. MEIER-SCHROERS M, Marx C, Schmeel FC, Wolter K, et al
    Revised PROPELLER for T2-weighted imaging of the prostate at 3 Tesla: impact on lesion detection and PI-RADS classification.
    Eur Radiol. 2018;28:24-30.
    PubMed     Abstract available
    
    
    
61. ULLRICH T, Quentin M, Schmaltz AK, Arsov C, et al
    Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate.
    Eur Radiol. 2018;28:17-23.
    PubMed     Abstract available
    
    
    
62. MARIOTTI GC, Falsarella PM, Garcia RG, Queiroz MRG, et al
    Incremental diagnostic value of targeted biopsy using mpMRI-TRUS fusion versus 14-fragments prostatic biopsy: a prospective controlled study.
    Eur Radiol. 2018;28:11-16.
    PubMed     Abstract available
    
    
    December 2017
63. BREMBILLA G, Dell'Oglio P, Stabile A, Ambrosi A, et al
    Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection.
    Eur Radiol. 2017 Dec 21. pii: 10.1007/s00330-017-5229.
    PubMed     Abstract available
    
    
    
64. BAUR ADJ, Schwabe J, Rogasch J, Maxeiner A, et al
    A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness.
    Eur Radiol. 2017 Dec 13. pii: 10.1007/s00330-017-5192.
    PubMed     Abstract available
    
    
    
65. BARRETT T, McLean M, Priest AN, Lawrence EM, et al
    Diagnostic evaluation of magnetization transfer and diffusion kurtosis imaging for prostate cancer detection in a re-biopsy population.
    Eur Radiol. 2017 Dec 8. pii: 10.1007/s00330-017-5169.
    PubMed     Abstract available
    
    
    October 2017
66. REISAETER LAR, Futterer JJ, Losnegard A, Nygard Y, et al
    Optimising preoperative risk stratification tools for prostate cancer using mpMRI.
    Eur Radiol. 2017 Oct 6. doi: 10.1007/s00330-017-5031.
    PubMed     Abstract available
    
    
    September 2017
67. IYAMA Y, Nakaura T, Katahira K, Iyama A, et al
    Development and validation of a logistic regression model to distinguish transition zone cancers from benign prostatic hyperplasia on multi-parametric prostate MRI.
    Eur Radiol. 2017;27:3600-3608.
    PubMed     Abstract available
    
    
    August 2017
68. HAUSMANN D, Aksoz N, von Hardenberg J, Martini T, et al
    Prostate cancer detection among readers with different degree of experience using ultra-high b-value diffusion-weighted Imaging: Is a non-contrast protocol sufficient to detect significant cancer?
    Eur Radiol. 2017 Aug 10. doi: 10.1007/s00330-017-5004.
    PubMed     Abstract available
    
    
    
69. JANSSEN JC, Meissner S, Woythal N, Prasad V, et al
    Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.
    Eur Radiol. 2017 Aug 4. doi: 10.1007/s00330-017-4994.
    PubMed     Abstract available
    
    
    
70. MUELLER-LISSE UG, Murer S, Mueller-Lisse UL, Kuhn M, et al
    Everyman's prostate phantom: kiwi-fruit substitute for human prostates at magnetic resonance imaging, diffusion-weighted imaging and magnetic resonance spectroscopy.
    Eur Radiol. 2017;27:3362-3371.
    PubMed     Abstract available
    
    
    
71. OLSON MC, Atwell TD, Mynderse LA, King BF, et al
    CT-guided transgluteal biopsy for systematic sampling of the prostate in patients without rectal access: a 13-year single-center experience.
    Eur Radiol. 2017;27:3326-3332.
    PubMed     Abstract available
    
    
    July 2017
72. PARK SY, Shin SJ, Jung DC, Cho NH, et al
    PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer.
    Eur Radiol. 2017;27:2776-2783.
    PubMed     Abstract available
    
    
    June 2017
73. ZHANG L, Tang M, Chen S, Lei X, et al
    A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer.
    Eur Radiol. 2017 Jun 27. doi: 10.1007/s00330-017-4843.
    PubMed     Abstract available
    
    
    
74. BATES A, Miles K
    Prostate-specific membrane antigen PET/MRI validation of MR textural analysis for detection of transition zone prostate cancer.
    Eur Radiol. 2017 Jun 12. doi: 10.1007/s00330-017-4877.
    PubMed     Abstract available
    
    
    
75. HANSEN NL, Koo BC, Gallagher FA, Warren AY, et al
    Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy.
    Eur Radiol. 2017;27:2259-2266.
    PubMed     Abstract available
    
    
    May 2017
76. GIGANTI F, Moore CM, Robertson NL, McCartan N, et al
    MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial.
    Eur Radiol. 2017 May 18. doi: 10.1007/s00330-017-4858.
    PubMed     Abstract available
    
    
    
77. DE VISSCHERE PJ, Vral A, Perletti G, Pattyn E, et al
    Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate.
    Eur Radiol. 2017;27:2095-2109.
    PubMed     Abstract available
    
    
    
78. ROUVIERE O, Melodelima C, Hoang Dinh A, Bratan F, et al
    Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study.
    Eur Radiol. 2017;27:1858-1866.
    PubMed     Abstract available
    
    
    April 2017
79. OVERDUIN CG, Jenniskens SF, Sedelaar JP, Bomers JG, et al
    Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes.
    Eur Radiol. 2017 Apr 13. doi: 10.1007/s00330-017-4833.
    PubMed     Abstract available
    
    
    
80. WANG J, Wu CJ, Bao ML, Zhang J, et al
    Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer.
    Eur Radiol. 2017 Apr 3. doi: 10.1007/s00330-017-4800.
    PubMed     Abstract available
    
    
    
81. BOMERS JG, Bosboom DG, Tigelaar GH, Sabisch J, et al
    Feasibility of a 2nd generation MR-compatible manipulator for transrectal prostate biopsy guidance.
    Eur Radiol. 2017;27:1776-1782.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: